MelloMonday, 19th February 2024, 5pm - 8pm


5:00pm James Ashton, CEO at the Quoted Companies Alliance presents What is the QCA?
5:30pm Company presentation by Poolbeg Pharma
6:00pm Company presentation by Time Finance
6:30pm Trading Update from Duke Royalty
6:50pm BASH Panel with Mark Simpson (SDG), Kevin Taylor (ALU) & Graham Neary (SUP)

James Ashton, CEO at the Quoted Companies Alliance  (QCA) – What is the QCA?

James Ashton, CEO, QCA

Company Presentation – Poolbeg Pharma 

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues.

Poolbeg’s clinical programmes target large addressable markets including CRS induced by cancer immunotherapies, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Jeremy Skillington began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licencing, investment and collaboration transactions.  Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH.

Jeremy joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September 2020 for €380M (£325M) upfront and significant downstream milestones.  Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D.  He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck.

Jeremy Skillington, Chief Executive Officer

David Allmond, Chief Business Officer

David is a passionate, life sciences professional, with a particular interest in strategy development. He has an impressive multi-national leadership background and in recent years has focused his career on global commercialisation of medicines to tackle severely underserved, debilitating cancers and orphan diseases. David has held a number of senior positions across the pharmaceutical industry: Chief Business Officer for Amryt Pharma plc, a global pharmaceutical company focused on developing and delivering innovative treatments to improve the lives of people with rare and orphan diseases. David was instrumental in putting in place the global commercial infrastructure at Amryt which enabled its revenue growth from c. $1.5 million when he joined in 2016, to approaching US$250 million some six years later. President EMEA for Aegerion Pharmaceuticals where he was responsible for the EMEA P&L and was tasked with turning the business around to ensure it was fit to deliver profitable growth, after a challenging entry into the region. General manager Celgene UK, responsible for setting up Celgene’s UK and Ireland operating company and subsequently Vice President EMEA Marketing and Market Access followed by his move to the US to assume the role of Corporate Vice President, Global Marketing for Celgene, where he played a pivotal role in defining global brand and portfolio strategy. David spent nearly 7 years on the board of Myeloma UK, a highly progressive patient group, supporting patients with Multiple Myeloma and now sits on the Board of GAFFI focused on tackling fungal disease in at risk populations in low to middle income countries. He holds a Bachelor of Science degree in Microbiology from Imperial College, London.

Company presentation – Time Finance

Time Finance plc provides finance to UK businesses helping them fund their businesses. It offers a multi-product range of funding solutions with a core focus on asset, loan and invoice finance. While focussed on being an ‘own-book’ lender and lending from its own balance sheet, it does retain the ability to broke-on deals where appropriate, enabling it to optimize business levels through market and economic cycles.

Ed Rimmer, Group CEO, has worked within commercial finance for well over 25 years holding many senior roles, including UK CEO of Bibby Financial Services. Ed has been involved with Time since 2017 having previously been Managing Director of the Invoice Finance Division and, more latterly, Group COO. Ed became Group CEO in June 2021.


James Roberts, CFO, qualified as an accountant with PwC and has worked in financial services for well over 20 years. He has held leadership positions with several AIM listed companies and has significant experience in mergers and acquisitions within fast-paced, growing businesses. James joined Time Finance as its CFO in May 2017.


Trading Update – Duke Royalty

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and abroad, combining the best features of both equity and debt.

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique ‘corporate mortgage’ while also aligning its returns to grow with the success of the business.

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. It’s three investment pillars are capital preservation, attractive dividend yield, and provide upside upon exits.

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

Neil Johnson is Duke’s Chief Executive Officer with responsibility for the overall strategic direction and performance of the company. Working closely with the other Board members and the Investment Committee, he leads all deal origination, due diligence and structuring.

Mr. Johnson has approximately 30 years of experience in investment banking, merchant banking, and research analysis in both the Canadian and UK capital markets. In 2012 he co-founded and became Chief Executive Officer of Difference Capital Financial, a Canadian publicly listed merchant bank. For the previous 19 years he worked for Canaccord Genuity, first in Canada and later at Canaccord London rising to the positions of Head of Corporate Finance (Europe), Global Head of Technology, and a member of the Global Executive Committee.

The Mello BASH (Buy, Avoid, Sell, Hold)

Mark Simpson Private Investor

Kevin Taylor Private Investor

MelloMonday Sponsors

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise.

Click here for Hardman & Co research.

Progressive introduces you to new investment ideas. FCA authorised and regulated, we provide freely available equity research and connect investors with companies across every sector of the market.  

Click here to receive our research and be invited to our regular investor events.